A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily With Adjunctive Computerized Cognitive Training Over 12 Week Treatment Period in Patients With Schizophrenia
Latest Information Update: 20 Nov 2023
At a glance
- Drugs Iclepertin (Primary)
- Indications Schizophrenia
- Focus Proof of concept; Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 07 Nov 2022 Status changed from active, no longer recruiting to completed.
- 18 Oct 2022 Results(n=183) assessing the efficacy of BI 425809 together with at home computerised cognitive training in patients with schizophrenia as part of a global multicentre trial presented at the 35th Annual Congress of the European College of Neuropsychopharmacology
- 28 Jun 2022 Status changed from recruiting to active, no longer recruiting.